Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis
Sponsor: Amgen
This PHASE3 trial investigates Osteopenia and Osteoporosis and is currently completed. Amgen leads this study, which shows 13 recorded versions since 2007 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2020 — Aug 2020 [monthly]
Completed PHASE3
-
Aug 2019 — Jun 2020 [monthly]
Completed PHASE3
-
Mar 2019 — Aug 2019 [monthly]
Completed PHASE3
-
Sep 2018 — Mar 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.